Company profile

Imbioray (Hangzhou) Biomedicine Co., Ltd.

Privately held: no public share price (Private CAR-NK cell-therapy company; RMB 230M Series A in 2022, no listing found. [resolved 2026-08-05 by resolve-null-is-public; source: https://pitchbook.com/profiles/company/492711-04]) · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
IBR733
Phase 1
CD33 / CLL-1 (CLEC12A)
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.